Compare Inovio Pharmaceuticals Inc (INO) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Teladoc Health Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Teladoc Health Inc trades at $9.66 (market cap $1.74B). The key difference: Teladoc Health Inc is far larger — about 19.5× Inovio Pharmaceuticals Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | TDOC | |
|---|---|---|
Market Cap | $89.27M | $1.74B |
Sector | Health | Health |
52-Week High | $2.87 | $9.72 |
52-Week Low | $1.05 | $4.47 |
Enterprise Value | $60.28M | $2.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
TDOC trades at $9.63, up 2.12% today, with a bullish technical signal from moving averages and a neutral RSI near 60. Revenue remains stable around $2.5 billion, but net losses persist with a -6.81% margin. Recent news highlights expansion through the Walmart partnership and upcoming Q2 2026 earnings. The stock shows resilience despite negative profitability, supported by a low P/S ratio of 0.67 and improving cash flow trends from operations.
Outlook is mixed: cost-cutting and partnerships offer growth potential, but sustained losses and high debt pose risks. Analysts are cautious with a $8.75 price target below current levels, reflecting concerns over profitability. Investors should weigh the recovery narrative against financial challenges, with earnings on July 29, 2026, as a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
